sorafenib has been researched along with Leukemia, Myeloid in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CN; Chen, CH; Chen, GS; Chen, YC; Chern, JW; Chou, NT; Chou, SH; Hseu, TH; Hsu, HC; Hu, TL; Huang, CH; Hwang, CS; Khanwelkar, RR; Ko, CH; Lee, O; Lin, HC; Lin, MW; Liu, CP; Shih, YC; Tsai, YJ; Tseng, HW; Tu, CM; Wang, HC; Wang, LM; Yu, CW | 1 |
| Abulkhair, HS; Fayed, EA; Husseiny, EM; Othman, EM | 1 |
| Bao, XB; Chen, SN; Ding, ZX; He, J; Li, Z; Liu, H; Liu, SB; Qiu, QC; Shen, HJ; Wang, C; Xue, SL; Yang, J; Yao, H | 1 |
| Gabrilove, J; Gong, P; Jing, Y; Li, Y; Wang, R; Waxman, S | 1 |
| Bose, P; Cortes, JE; Dalle, IA; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, HM; Loghavi, S; Naqvi, K; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, N; Yalniz, F; Yilmaz, M | 1 |
| Burchert, A; Chaturvedi, A; Eilers, M; Enghofer, E; Metzelder, S; Neubauer, A; Teichler, S; Wang, Y; Wanzel, M; Wollmer, E | 1 |
| Polliack, A; Tadmor, T; Tallman, MS | 1 |
| Brandwein, J; Buckstein, R; Crump, M; Eisenhauer, E; Hedley, D; Kamel-Reid, S; Kassis, J; Leber, B; Matthews, J; McIntosh, L; Minden, M; Robinson, S; Seymour, L; Turner, R; Wells, R | 1 |
| Lowe, SW; Pardee, TS; Zuber, J | 1 |
| Attkisson, E; Aust, MM; Ferreira-Gonzalez, A; Grant, S; Rahmani, M; Williams, DC | 1 |
| Abriola, L; Auclair, D; Burd, A; Carter, C; Chang, Y; Dumas, J; Gedrich, R; Lynch, M; Miller, D; Pickett, W; Rocks, S; Shi, H; Trail, PA; Vasavada, H; Wilhelm, SM; Wilkie, D; Yatsula, V; Zhang, X | 1 |
| Clemetson, KJ | 1 |
1 trial(s) available for sorafenib and Leukemia, Myeloid
| Article | Year |
|---|---|
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
11 other study(ies) available for sorafenib and Leukemia, Myeloid
| Article | Year |
|---|---|
Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.
Topics: Animals; Aurora Kinases; Binding Sites; Cell Line, Tumor; Computer Simulation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Transplantation, Heterologous; Urea | 2010 |
The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Molecular Docking Simulation; Molecular Structure; Semicarbazones; Sorafenib; Structure-Activity Relationship; Thiosemicarbazones; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
Topics: Acute Disease; Adult; Asian People; China; Drug Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Sorafenib; Synthetic Lethal Mutations; Tandem Repeat Sequences; THP-1 Cells; Xenograft Model Antitumor Assays | 2018 |
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Remission Induction; Sorafenib; Staurosporine; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2019 |
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2009 |
Sorafenib - a small molecule with big promise?
Topics: Abdominal Pain; Acute Disease; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fatigue; Humans; Leukemia, Myeloid; Metabolic Clearance Rate; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Cytarabine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Lymphoid Leukemia Protein; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Survival Analysis; Tandem Repeat Sequences; Tumor Suppressor Protein p53 | 2011 |
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cells, Cultured; Drug Synergism; Female; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; Sorafenib; U937 Cells; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Humans; Kidney; Leukemia, Myeloid; Mice; Mice, Nude; Mutant Proteins; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recombinant Fusion Proteins; Sorafenib; Tandem Repeat Sequences; Transfection; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD40 Antigens; Diphenylamine; Hematologic Neoplasms; Hematology; Humans; Ki-1 Antigen; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2007 |